An analysis of the pharmacokinetics of high dose intravenous Melphalan in multiple myeloma.

被引：0
|
作者：
Kalakonda, N [1 ]
Welby-Everard, P [1 ]
Dougal, M [1 ]
Ranson, M [1 ]
Scarffe, JH [1 ]
Chopra, R [1 ]
机构：
[1] Christie Hosp, Dept Haematol & Oncol, Manchester, Lancs, England
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4661
引用
收藏
页码：321B / 321B
页数：1
相关论文
共 50 条
  • [31] BORTEZOMIB, LOW DOSE INTRAVENOUS MELPHALAN AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED MULTIPLE MYELOMA
    Popat, R.
    Oakervee, H.
    Williams, C.
    Cook, M.
    Craddock, C.
    Basu, S.
    Singer, C.
    Odeh, L.
    Foot, N.
    Joel, S.
    Hallam, S.
    Harding, S.
    Mead, G.
    Cavenagh, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 365 - 366
  • [32] HIGH-DOSE INTRAVENOUS MELPHALAN IN A PATIENT WITH MULTIPLE-MYELOMA AND OLIGURIC RENAL-FAILURE
    PECHERSTORFER, M
    ZIMMERROTH, I
    WEIDINGER, S
    IRSIGLER, K
    HALBMAYER, WM
    ULRICH, W
    FISCHER, M
    BAUMGARTNER, G
    CLINICAL INVESTIGATOR, 1994, 72 (07): : 522 - 525
  • [33] HIGH-DOSE MELPHALAN (HDM) IN MULTIPLE-MYELOMA
    SELBY, P
    POWLES, R
    ROBINSON, B
    VINCENT, M
    MCELWAIN, TJ
    BRITISH JOURNAL OF CANCER, 1984, 50 (02) : 247 - 247
  • [34] Outpatient high-dose melphalan in multiple myeloma patients
    Kassar, Mohamad
    Medoff, Erin
    Seropian, Stuart
    Cooper, Dennis L.
    TRANSFUSION, 2007, 47 (01) : 115 - 119
  • [35] Arsenic trioxide with ascorbic acid and high-dose melphalan for autologous hematopoietic stem cell transplantation for multiple myeloma.
    Qazilbash, Muzaffar H.
    Saliba, Rima M.
    Davis, Marilyn S.
    Mendoza, Floralyn L.
    Hosing, Chitra
    Couriel, Daniel R.
    De Lima, Marcos
    Kebriaei, Partow
    Weber, Donna M.
    Wang, Michael
    Alousi, Arnin M.
    Matthes, Steven G.
    Jones, Roy B.
    Champlin, Richard E.
    Giralt, Sergio A.
    BLOOD, 2006, 108 (11) : 881A - 881A
  • [36] High dose idarubicin, melphalan and cyclophosphamide for treatment of multiple myeloma
    Schneider, P
    Söhngen, D
    Kobbe, G
    Bauser, U
    Hünerliturkoglu, A
    Heyll, A
    Aul, C
    BONE MARROW TRANSPLANTATION, 1998, 21 : S203 - S203
  • [37] MODELING THROMBOCYTOPENIA AS A PREDICTOR OF OUTCOMES FOLLOWING SINGLE, HIGH--DOSE MELPHALAN AND STEM CELL TRANSPLANT IN MULTIPLE MYELOMA.
    Irby, D.
    Cottini, F.
    Hade, E.
    Hofmeister, C.
    Phelps, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S27 - S27
  • [38] A phase I study of the safety, tolerance, pharmacokinetics, antigenicity and efficacy of a single intravenous dose of AHM followed by multiple doses of intravenous AHM in patients with multiple myeloma.
    Powles, R
    Sirohi, B
    Morgan, G
    Milligan, D
    Yong, K
    Cook, G
    Williams, C
    Ozaki, S
    Kosaka, M
    Goyal, S
    Linch, D
    BLOOD, 2001, 98 (11) : 165A - 165A
  • [39] High-dose idarubicine, busulphan and melphalan for autologous stem cell transplantation in multiple myeloma. Comparison with an historical control
    Capria, S
    Ribersani, M
    Ferrazza, G
    Micozzi, A
    Petrucci, MT
    Simone, F
    Torromeo, MC
    Trisolini, SM
    Mandelli, F
    Meloni, G
    BONE MARROW TRANSPLANTATION, 2003, 31 : S81 - S82
  • [40] USE OF INTRAVENOUS MELPHALAN IN TREATMENT OF MULTIPLE MYELOMA
    BALMES, A
    DAUVERCH.J
    OTHONIEL, J
    MANDIN, A
    CHAVANET.F
    PRESSE MEDICALE, 1971, 79 (23): : 1072 - &
12345